Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Critical Appraisal Of Continuous Glucose Monitoring Technology Is Focus Of Diabetes Technology & Therapeutics Supplement
Continuous Glucose Monitoring (CGM) devices represent a critical step toward achieving automated glucose measurement, offering people with diabetes a promising new tool for maintaining optimal glucose control. A comprehensive review of this rapidly changing field, featuring the most recent research findings and critical analysis, is the focus of a special supplement of Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. The supplement is available free online at http://www.liebertonline.com/dia

Labopharm Files New Drug Submission With Health Canada For Novel Antidepressant
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) announced it has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada for its novel formulation of the antidepressant trazodone.
News of the day
BioCis Pharma Reports Positive Phase IIa Clinical Results In Atopic Dermatitis
BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company"s novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks. The objectives were to evaluate the tolerability, pharmacokinetics, and efficacy of the topical treatment.
Medical Devices

NACDS, NCPA Endorse Rep. Mike Ross' Medication Therapy Management Legislation

Today, the National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) announced their support for H.R. 3108, the Medication Therapy Management Benefits Act of 2009, sponsored by Rep. Mike Ross (D-AR). The bill was introduced on Friday June 26, 2009, and was immediately referred to the Committee on Energy and Commerce and Committee on Ways and Means, two House committees with jurisdiction over comprehensive healthcare reform legislation. Pharmacist-provided medication therapy management (MTM) involves a licensed pharmacist"s work with a patient to review, monitor, and identify problems with a patient"s medication plan. "We appreciate the hard-work and dedication of Rep. Ross as he continues to advocate for pro-patient and pro-pharmacy healthcare reform legislation in Congress," stated NACDS President and Chief Executive Officer Steven C. Anderson, IOM, CAE. "Rep. Ross" bill signifies the importance of pharmacist-provided medication therapy management for improving medication adherence, enhancing patient health, and reducing long-term healthcare costs." "Medication therapy management is a gateway to improving patient adherence and their outcomes by utilizing the clinical expertise of pharmacists," said Bruce T. Roberts, RPh, NCPA Executive Vice President and CEO. "H.R. 3108 will expand the pool of Medicare Part D patients that can access this valuable service and recognize pharmacists for the savings they provide to the healthcare system. We thank Congressman Mike Ross for introducing this bill, and urge other members of the House to support it. We call on the Senate to introduce similar legislation. Ultimately for health care reform to be fully successful, it must include proposals such as this to improve quality while lowering overall costs." Poor medication adherence has been estimated to cost over $177 billion per year, according to an article by Frank R. Ernst, PharmD, and Amy J. Grizzle, PharmD, "Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness Model," published in the Journal of the American Pharmaceutical Association. This article was published in 2001, and it is widely anticipated that this figure has risen substantially since that time. Direct and indirect costs include loss of productivity, increased emergency room visits and hospitalizations, among others. Studies have shown that MTM reduces health complications and costs. For example, one Blue Cross/Blue Shield of Minnesota study showed a reduction of $12 in overall healthcare costs for every $1 invested in MTM. National Association of Chain Drug Stores


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009